Obsidian Therapeutics, Inc. Common Stock Total Assets
Obsidian Therapeutics, Inc. Common Stock total assets. Based on the latest financial reports, Obsidian Therapeutics, Inc. Common Stock (OBX) holds total assets worth $70.14 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see cash flow conversion of Obsidian Therapeutics, Inc. Common Stock for how efficiently the company converts equity into cash flow.
Total Assets of Obsidian Therapeutics, Inc. Common Stock (2024–2025)
Total assets of Obsidian Therapeutics, Inc. Common Stock from 2024 to 2025. This chart illustrates how Obsidian Therapeutics, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See Obsidian Therapeutics, Inc. Common Stock (OBX) stock price for real-time trading data and today's change.
Obsidian Therapeutics, Inc. Common Stock - Asset Composition Analysis
Obsidian Therapeutics, Inc. Common Stock Total Assets Breakdown (December 2025)
Obsidian Therapeutics, Inc. Common Stock total assets breakdown as of December 2025. Obsidian Therapeutics, Inc. Common Stock's total assets of $70.14 Million consist of 92.0% current assets and 8.0% non-current assets. Explore Obsidian Therapeutics, Inc. Common Stock (OBX) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 45.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2024–2025)
This chart illustrates how Obsidian Therapeutics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Obsidian Therapeutics, Inc. Common Stock's current assets represent 92.0% of total assets in 2025, a decrease from 94.1% in 2024.
- Cash Position: Cash and equivalents constituted 45.6% of total assets in 2025, up from 27.1% in 2024.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2024.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Obsidian Therapeutics, Inc. Common Stock Competitors by Total Assets
Key competitors of Obsidian Therapeutics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Braveheart Bio, Inc. Common Stock
NASDAQ:BRVE
|
USA | $126.96 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.98 Billion |
Obsidian Therapeutics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.21 | - | - |
| Quick Ratio | 4.21 | - | - |
| Cash Ratio | 0.00 | - | - |
| Working Capital | $48.81 Million | - | - |
Obsidian Therapeutics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Obsidian Therapeutics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 10.13 |
| Asset Growth Rate (YoY) | -51.8% |
| Total Assets | $88.58 Million |
| Market Capitalization | $896.94 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Obsidian Therapeutics, Inc. Common Stock's assets at a significant premium (10.13x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Obsidian Therapeutics, Inc. Common Stock's assets decreased by 51.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Obsidian Therapeutics, Inc. Common Stock (2024–2025)
The table below shows the annual total assets of Obsidian Therapeutics, Inc. Common Stock from 2024 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $88.58 Million | -51.78% |
| 2024-12-31 | $183.71 Million | -- |
About Obsidian Therapeutics, Inc. Common Stock
Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform de… Read more